<DOC>
	<DOCNO>NCT01972178</DOCNO>
	<brief_summary>The objective study - To evaluate efficacy PRC-4016 assessment percentage change blood lipid lipoprotein parameter baseline 12 week treatment - To evaluate safety PRC-4016 assess adverse event safety parameter</brief_summary>
	<brief_title>Efficacy Safety PRC-4016 Subjects With Mixed Dyslipidemia</brief_title>
	<detailed_description>6-8 week screen period diet/lifestyle stabilization lipid qualification</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Main Fasting triglycerides 200499 mg/dl NonHDLC &gt; 130 mg/dl Stable statin treatment Type I diabetes uncontrolled type II diabetes Recent cardiovascular coronary event History pancreatitis History evidence major clinically significant disease would interfere conduct study interpretation data Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>